Particularly, this multicenter observational study tried to highlight the robustness of technical workflows adopted by each participating center in the detection of the aberrant MET transcript for targeted therapy of selected NSCLC patients [7,9]. The gene discussed is MET; the disease is non-small cell lung carcinoma.